🏛️ Verified NIH Record • Updated 2026-08-26
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) (NCT06881784)
🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Revolution Medicines, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (6 items).
Location: Alabama Oncology — Birmingham, Alabama
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Prior therapy with direct RAS-targeted therapy or docetaxel.
- Untreated central nervous system (CNS) metastases.
- Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).
- Ongoing anticancer therapy.
- Pregnant or breastfeeding.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (153 Sites)
- Alabama Oncology — Birmingham, Alabama
- MemorialCare Long Beach Medical Center — Long Beach, California
- Yale University, Smillow Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists & Research Institute - South — Fort Myers, Florida
- BRCR Global — Plantation, Florida
- Cancer Care Centers of Breevard — Rockledge, Florida
- Florida Cancer Specialists & Research Institute - North — St. Petersburg, Florida
- Cleveland Clinic Martin North — Stuart, Florida
- Florida Cancer Specialists & Research Institute - East — West Palm Beach, Florida
- University Cancer and Blood Center — Athens, Georgia
- Piedmont Healthcare, Inc — Atlanta, Georgia
- Winship Cancer Institute — Atlanta, Georgia
- Center for Care and Discovery — Chicago, Illinois
- University of Iowa Health Care Cancer Services Quad Cities — Bettendorf, Iowa
- University of Iowa Hospitals & Clinics — Iowa City, Iowa
- University of Iowa Health Care, Mission Cancer + Blood — Waukee, Iowa
- The University of Kansas Cancer Center — Westwood, Kansas
- Johns Hopkins University of Medicine — Baltimore, Maryland
- Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Health — Detroit, Michigan
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
- St. Vincent Frontier Cancer Center — Billings, Montana
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
- John Theurer Cancer Center at Hackensack UMC — Hackensack, New Jersey
- Morristown Medical Center (MMCORC) — Morristown, New Jersey
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.